radiolabelling

R&D

The development experience with GLP-1 analogues offers critical insights for navigating ADME challenges in contemporary peptide programmes.

News

Intellia has reported the first-ever phase 3 results with an in vivo gene-editing therapy, CRISPR-based lonvo-z for hereditary angioedema.

Sales & Marketing

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.